Summary.-The effects of hormone and drug treatments on plasma prolactin (PRL) levels and mammary tumour growth were investigated in rats bearing continuously growing DMBA-induced mammary tumours that responded to bilateral adrenoovariectomy (Ax+ Ox). Oestrogen (E2) administration increased both plasma PRL and tumour growth, but was unable to sustain tumour growth when the PRL level was reduced by concurrent injection of ergocornine (Eg). Perphenazine (P,) produced a dose-related increase in plasma PRL, but stimulation of tumour growth in the absence of E2 required a minimal level of plasma PRL induced by Pz (0-15 mg/100 g body wt/day or more). Progesterone (P) (3 mg/day) alone, although without effect on PRL levels, maintained static tumour growth (i.e. it had a slight stimulatory effect) irrespective of the duration of treatment. The increase in plasma PRL levels above the basal values in the Ax + Ox controls following injections of combined P + P, (0 1 mg/100 g/day) was sufficient to sustain static tumour growth, but not to reactivate growth. Enhancement of both plasma PRL and tumour growth did not occur until P and higher doses of Pz (0.3 mg/100 g/day) were injected jointly; this treatment, however, while unable to stimulate continuous tumour growth, was able to maintain static growth when plasma PRL was reduced by concurrent injections of P+Pz+Eg. From these findings it is postulated that the mechanism of action whereby P maintains static tumour growth is different from that of PRL and independent of circulating PRL levels.
THE MAJORITY of rat tumours induced by 7, 12 -dimethylbenz -(a) -anthracene (DMBA) are hormone-dependent, as shown by their regression after ovariectomy (Ox), adrenalectomy (Ax) and hypophysectomy (Pearson et al., 1969) . Oestrogens (E2) and prolactin (PRL) have been shown to influence the growth of such tumours (Pearson et al., 1969) . The dose-effect relationship of PRL on mammary tumour growth and the duration of PRL-induced stimulation of tumour growth, in the Ax + Ox rat, is a matter of debate. After Ax + Ox, Nagasawa & Yanai (1970) reported that resumption of tumour growth was not only temporary, but stimulated only on high doses of PRL, whilst Pearson et al. (1969) found that low or high doses of PRL were equally effective. Reported plasma PRL levels in rats bearing DMBA-induced mammary cancers is also contradictory, both normal (Nagasawa et al., 1973) and raised values having been found (Teller et al., 1977) .
Although progesterone (P) enhances induction of DMBA tumours (Jabara, 1967) its role in the growth of established tumours is unclear and conflicting. Horwitz & McGuire (1977) demonstrated that P alone failed to sustain tumour growth after Ax + Ox, despite the initial presence of P receptor (i.e., their results suggested that E2 is an absolute necessity at the tumour site). Kelly et al. (1977) , on the other hand, reported a similar effect of P, even though the level of E2 was still appreciable, but lowered, by Ox.
The present experiments were designed to clarify the above findings by determining the effects and mechanisms of action of (i) P, (ii) PRL, induced by perphenazine (Ps) and (iii) P + P,, on the growth of DMBA-induced mammary carcinomas and on plasma PRL levels in Ax + Ox rats.
MATERIALS AND METHODS
Treatment of animals.-Two hundred and twenty virgin female random-bred SpragueDawley rats, weighing 120 + 20 g and fed commercial pellets and tap water ad libitum, were housed 5 rats/cage. At 50 days of age, they each received a single intragastric dose of 30 mg DMBA (Eastman Organic Chemicals, U.S.A.) dissolved in 2 ml maize oil. Beginning 4 weeks after DMBA administration, all rats were palpated weekly and any mammary tumour recorded, measured and graphed as described previously (Jabara, 1967) . Rats bearing at least one continuously growing tumour were allocated randomly to one of 6 groups (Table I) . A tumour was designated as "growing continuously" if the size of the neoplastic mass steadily increased during the course of at least 5 weekly measurements. When these tumours had reached a diameter of ' 2 cm, the rats were weighed and given bilateral Ax + Ox. Thereafter they had access to both saline (0-9%) and tap water, and received s.c. injections of deoxycorticosterone acetate (Calbiochem, N.S.W.), 0-1 mg/ 100 g body weight/2 days, dissolved in 0-1 ml maize oil, to assist sodium retention. When the continuously growing tumours had regressed to half their original preoperative size (14 days on average) (Figs 1-4 ) the rats were injected s.c., once daily, with oestradiol17f (E2) (Calbiochem, N.S.W.), progesterone (P) (Sigma Chemical Co., U.S.A.), perphenazine (Pz) ("Trilafon", Schering Corp., U.S.A.), ergocornine hydrogenmaleinate (Eg) (Sandoz, Switzerland) or combinations, in the doses and for the periods shown in Table I. P and E2 were dissolved in maize oil, P, in 0-9% saline and Eg in 15% ethanol made up with 0-9% saline. Daily vaginal smears were taken at about 09:00 from all rats in Group 1, to ensure that the animals remained in an oestrus-like state.
Following Ax + Ox, the skin over each tumour was kept shaved and each neoplasm was measured and graphed twice weekly until the end of the experiment. At necropsy each rat was weighed, and portions of each mammary tumour were labelled as to site and side, fixed in 10% buffered formalin and 5,um paraffin sections were stained with haematoxylin and eosin.
Blood sampling and PRL assay.-As ether anaesthesia has been shown to increase serum PRL levels in experimental animals (Linke & Niswender, 1972) , each rat was etherized for a standard period of 40 sec before 0 4 ml of blood from the caudal vein was collected into heparinized tubes, just before a particular hormone injection, and at various times between 1 and 30 days afterwards. The blood was centrifuged at 1100 g for 10 min, and the plasma stored at -20°C until PRL levels were assayed.
Plasma PRL was measured by the radioimmunoassay method supplied with the NIAMD kit, with only minor modifications. Duplicates were run for each sample and, in order to avoid interassay variation, samples from a complete experiment were assayed at the same time. Results were expressed in terms of the NIAMD-Rat Prolactin-RP-1 standard supplied with the kit.
Statistical analysis.-The patterns ofgrowth of the mammary carcinomas were calculated from the slopes for the regression lines for individual rats under similar treatments, by the method described by Rees & Westwood (1974) , except that the present data did not require a logarithmic transformation of the results, as they fitted straight lines. Comparison of the growth characteristics of 2 treatment groups was made by comparing the common slope for each group by t test. A common slope for the regression lines for rats under similar treatments can be justified by an analysis of variance for all points for all rats under that treatment. A pooled estimate for this slope was used in the calculations (Armitage, 1971) .
Comparison of the mean serum prolactin concentrations between different treatments was made by t test, the correlation coefficients being computed in the standard manner (Schefler, 1969) .
RESULTS

Tumour incidences
Of 220 rats fed DMBA, 194 (88%) Adreno-ovariectomy caused a marked regression in the size of continuously growing neoplasms (P < 001). E2 induced reactivation of tumour growth (P < 0.01), whereas E2 + Eg decreased the size of these neoplasms (P < 0 01).
Injections of P (3 mg/day for 30 days), in contrast, failed to reactivate tumour growth after Ax + Ox (Fig. 1) . The tumours regressed rapidly, however, when P injections were discontinued (P < 0.01) and remained static upon resumption of the P regime (Fig. 1) . Similarly, daily injections of P, (0-1 mg/100 g) or combined P + P, treatment to Groups 3 and 4, respectively, did not reactivate tumour growth (Figs. 2 and 3) ; the tumours regressed further after withdrawal of the P, regime in Group 3 (P < 0.05) (Fig. 2) . Doses of Pz>0I mg/100 g/day increased the tumour growth rate in proportion to the dose (Table II) . This correlation was significant (P < 0 001) within the limitations of the data, the rats sotreated only surviving between 4 and 10 days (Table II) . Of particular interest was the finding that combined P + Pz (0.3 mg/100 g/day) treatment to animals in Group 5 gradually increased their tumour sizes over 21 days, but the addition of Eg to this combination appeared to revert the neoplastic growth pattern to a static one (Fig. 5) for at least 7 days (the rats died at this point). Fifteen days' treatment with E2 increased the plasma prolactin (PRL) concentration (P < 0001) above the level in the Ax + Ox control group ( 112 + 5 4 ng/ ml). Administration of Eg + E2 to these rats significantly depressed the plasma PRL to Ax+Ox levels (P<0001). In contrast, P treatment did not alter the plasma PRL significantly from Ax + Ox levels, irrespective of the duration of its administration (Fig. 1) . P, (0 1 mg/lOO g/ day) increased the concentrations markedly above Ax + Ox levels (P < 0.05) (Fig. 2) . Cessation of P, injections led to a significant reduction in PRL level within 24 h (P < 0-001) decreasing to Ax + Ox levels by 21 days (Fig. 2 (Fig. 3) . A gradual but significant rise in the PRL levels was observed after 15 (P< 001) and 30 days (P< 001) respectively after combined P + P,, which were above those obtained at similar intervals after treatment with either hormone alone (Fig. 3) .
Increasing the daily dose of P, to 0 3 mg/lOO g significantly raised the plasma PRL levels both above Ax + Ox controls (P < 0-01) and above that of Group 3 (04 mg/ I00 g/day P,) (P < 0 01) 24 h after injection (Fig. 4) 8L. (C. MINASTAN-BATMANIAN AND A. G. JABARA before P treatment; however, the mean increase was only 12%0 compared with 70%0 in Group 4. Administration of Eg to these animals, in addition to P and Pz, effectively reduced the PRL levels after 24 h (P < 0.01) and, after 7 days, levels had returned to Ax+Ox control values (Fig. 4) .
Daily P, doses of 0 1 5-0 5 mg/I 00 g/day (Table II) (Fig. 2) and in Group 5 when only P + Pz was given (Fig. 4) .
Tumour types
All neoplasms used in these experiments were carcinomas. Tumours from animals in all groups other than Group 5, weighed up to 3 g and measured up to 1 cm (mean diameter); neoplasms from rats in Group 5 weighed up to 25 g and measured up to 3 4 cm (mean diameter). Microscopically, most mammary neoplasms in all 6 groups were papillary cystadenocarcinomas, while a few were classified as adenocarcinomas or solid, poorly differentiated carcinomas (Jabara, 1967) . No direct correlation was evident between tumour growth behaviour and histology of the carcinomas in Groups 1-6 and, apart from marked degenerative changes in carcinomas after E2 + Eg (Group 1), there was no apparent relationship between tumour histology and treatment of the host in any of the 6 groups of animals.
DISCUSSION
In agreement with previous findings (Pearson et al., 1969 ) E2 administration caused a significant increase in plasma PRL, and also reactivated growth of tumours which had regressed after Ax+ Ox. Subsequent concurrent injections of E2 + Eg induced macroscopic regression of these E2-dependent tumours, gross degenerative histological changes in the neoplasms, and markedly reduced plasma PRL levels (Shaar & Clemens, 1972) .
The observation that P, produced a dose-related increase in plasma PRL confirms the findings of Bogden et al. (1974) . Perphenazine is thought to raise plasma PRL levels by inhibiting dopaminergic transmission, either through suppression of hypothalamic PRL-inhibitory factor, or antagonism of that factor at the level of the pituitary, or both (Frantz, 1.978) . However, it is interesting to note that in the present experiment no increase in growth of otherwise static, hormoneresponsive tumours was apparent unless P, was administered in doses of 0 1 5 mg/ 100 g/day or more. In other words, a low dose of prolactin (i.e. 0 1 mg/100 g/day) was insufficient, to reactivate tumour growth, but was able to maintain static growth by slightly stimulating the tumour in order to sustain growth in the static phase. Active growth, on the other hand, appeared to require a certain minimal level of plasma PRL, as was also suggested from the work of Nagasawa & Yanai (1970) . They demonstrated that injections of ovine PRL (1.25 mg, twice daily for 20 days) to Ax + Ox rats bearing DMBAinduced mammary carcinomas, reactivated growth of the tumours only for the first 10 days, after which the neoplasms regressed; injection of the same dose of PRL 20 days after Ax + Ox had no effect on tumour growth. Enhancement of both the level of plasma PRL and of tumour growth up to 14 days from the start of injections did not occur until higher doses of Pz (0 3 mg/I00 g/day) were administered in accord with the findings of Nagasawa & Yanai (1970) . However, the duration of PRL-induced stimulation of tumour growth did not appear to be limited. Whether the tumours became so large as to render growth autonomous (Griswald & Green, 1970; Huggins & Yang, 1962) or whether growth simply cannot be sustained (Nagasawa & Yanai, 1970; Klaiber et al., 1969) which only maintained static tumour growth (i.e. a growth pattern which requires an equilibrium between cell gain and cell loss). Progesterone alone, though without effect on PRL levels, was found to maintain static tumour growth (i.e. it exerted a slight stimulatory effect on the tumour to sustain growth in a static phase). Kim (1965) also reported a similar effect of P on 3-methylcholanthrene-induced mammary tumours. P may possibly have some direct metabolic effect on the growth of these tumours, growth per se not appearing to be the important factor, but rather the biochemical consequence(s) of P. In any event it is interesting to note that P acts independently of circulating plasma PRL. Therefore the present findings indicate that P apparently acts by a different mechanism from PRL to maintain static growth, especially in view of the fact that P + P, high-dose treatment caused an additive increase in circulating PRL levels. It is postulated that P may be acting directly at the tumour site (Asselin et al., 1976) by inducing the synthesis of sufficient P receptor to maintain, but not increase, tumour growth. More extensive studies are needed, especially in the field of P receptors and the mapping of the complex sequence of events which accompany receptors, to evaluate this concept further. However, it seems unlikely that P is acting via an effect on PRL secretion since, despite basal Ax + Ox control PRL levels recorded after P and P + Pz + Eg treatments (Groups 2 and 5, respectively), tumour growth remained static and did not regress as would have been expected if PRL were involved. In addition, the hypothesis that E2 is mandatory for tumour growth cannot be supported by the present data, because 14 days after Ax + Ox, when plasma E2 levels would be expected to be minimal, it was noted that (i) high doses of P, were effective in markedly increasing tumour growth, and (ii) tumour growth remained static after P and P+Pz+Eg treatments. The first observation of this series is in agreement with that of Leung et al. (1975) , who found that PRL stimulated the growth of some endocrine-ablation-responsive tumours 7 or 11 days after Ax + Ox, but required E2 as well to stimulate others. The second observation contrasts with the report by Horwitz & McGuire (1977) and even more so with that of Kelly et al. (1977) , whose finding that P cannot maintain tumour growth after Ox in the presence of low but appreciable levels of plasma E2 is puzzling. Furthermore, the fact that rats receiving 3 mg P daily remain in almost continuous dioestrus (Jabara et al., 1972) fails to confirm the suggestion of Baggett et al. (1956) that P may be converted to E2 in vivo.
This study does not negate the importance of PRL and E2 in the growth of DMBA-induced mammary neoplasms, but suggests that alongside these hormones P may also play a vital part in the promotional stage of mammary carcinogenesis.
